Relatively few studies have explored these markers in ADHF [13,14,15,16,17], and the AKINESIS trial—the largest of such studies to date—showed no advantage of NGAL over plasma creatinine as a marker of AKI in ADHF [18]. The gene discussed is LCN2; the disease is acute kidney injury.